Stocks
Gilead Sciences Financial Statements (GILD) |
||||||||||
| Gilead Sciencessmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2021 | 23.02.2022 | 31.12.2022 | 22.02.2023 | 23.02.2024 | 12.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 24 689 | 27 305 | 27 281 | 27 281 | 27 116 | 28 730 | |||
| Operating Income, bln rub | 7 029 | 7 406 | 7 330 | 7 330 | 7 605 | 98.0 | ||||
| EBITDA, bln rub | ? | 4 133 | 11 329 | 6 775 | 8 852 | 10 496 | 139.0 | |||
| Net profit, bln rub | ? | 89.0 | 6 225 | 4 592 | 4 592 | 5 665 | -50.0 | |||
| OCF, bln rub | ? | 8 168 | 11 384 | 9 072 | 9 072 | 8 006 | 12 162 | |||
| CAPEX, bln rub | ? | 650.0 | 579.0 | 0.000 | 728.0 | 585.0 | 705.0 | |||
| FCF, bln rub | ? | 7 518 | 10 805 | 9 072 | 8 344 | 7 421 | 12 397 | |||
| Dividend payout, bln rub | 3 449 | 3 605 | 0.000 | 3 709 | 3 809 | 5 886 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 3 875% | 57.9% | 0.00% | 80.8% | 67.2% | -11 772% | ||||
| OPEX, bln rub | 10 190 | 10 609 | 14 294 | 10 650 | 13 013 | 13 533 | ||||
| Cost of production, bln rub | 4 572 | 6 601 | 5 657 | 5 657 | 5 968 | 39 113 | ||||
| R&D, bln rub | 5 039 | 5 363 | 4 977 | 4 977 | 6 923 | 5 661 | ||||
| Interest expenses, bln rub | 984.0 | 1 001 | 935.0 | 935.0 | 944.0 | 965.0 | ||||
| Assets, bln rub | 68 407 | 67 952 | 63 171 | 63 171 | 62 125 | 54 525 | ||||
| Net Assets, bln rub | ? | 18 221 | 21 064 | 0.000 | 21 209 | 22 833 | 18 474 | |||
| Debt, bln rub | 31 402 | 26 695 | 0.000 | 25 230 | 24 987 | 23 249 | ||||
| Cash, bln rub | 7 910 | 7 829 | 7 630 | 7 630 | 7 264 | 5 037 | ||||
| Net debt, bln rub | 23 492 | 18 866 | -7 630 | 17 600 | 17 723 | 18 212 | ||||
| Ordinary share price, rub | 58.3 | 72.6 | 85.9 | 85.9 | 81.0 | 81.7 | ||||
| Number of ordinary shares, mln | 1 257 | 1 256 | 1 255 | 1 255 | 1 248 | 1 247 | ||||
| Market cap, bln rub | 73 233 | 91 198 | 107 742 | 107 742 | 101 100 | 101 818 | ||||
| EV, bln rub | ? | 96 725 | 110 064 | 100 112 | 125 342 | 118 823 | 120 030 | |||
| Book value, bln rub | -23 013 | -20 723 | -37 208 | -15 999 | -11 935 | -10 386 | ||||
| EPS, rub | ? | 0.07 | 4.96 | 3.66 | 3.66 | 4.54 | -0.04 | |||
| FCF/share, rub | 5.98 | 8.60 | 7.23 | 6.65 | 5.95 | 9.94 | ||||
| BV/share, rub | -18.3 | -16.5 | -29.6 | -12.7 | -9.56 | -8.33 | ||||
| EBITDA margin, % | ? | 16.7% | 41.5% | 24.8% | 32.4% | 38.7% | 0.48% | |||
| Net margin, % | ? | 0.36% | 22.8% | 16.8% | 16.8% | 20.9% | -0.17% | |||
| FCF yield, % | ? | 10.3% | 11.8% | 8.42% | 7.74% | 7.34% | 12.2% | |||
| ROE, % | ? | 0.49% | 29.6% | 21.7% | 24.8% | -0.27% | ||||
| ROA, % | ? | 0.13% | 9.16% | 7.27% | 7.27% | 9.12% | -0.09% | |||
| P/E | ? | 822.8 | 14.7 | 23.5 | 23.5 | 17.8 | -2 036 | |||
| P/FCF | 9.74 | 8.44 | 11.9 | 12.9 | 13.6 | 8.21 | ||||
| P/S | ? | 2.97 | 3.34 | 3.95 | 3.95 | 3.73 | 3.54 | |||
| P/BV | ? | -3.18 | -4.40 | -2.90 | -6.73 | -8.47 | -9.80 | |||
| EV/EBITDA | ? | 23.4 | 9.72 | 14.8 | 14.2 | 11.3 | 863.5 | |||
| Debt/EBITDA | 5.68 | 1.67 | -1.13 | 1.99 | 1.69 | 131.0 | ||||
| R&D/CAPEX, % | 775.2% | 926.3% | 683.7% | 1 183% | 803.0% | |||||
| CAPEX/Revenue, % | 2.63% | 2.12% | 0.00% | 2.67% | 2.16% | 2.45% | ||||
| Gilead Sciences shareholders | ||||||||||
